Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 study.

Autor: Welker J; Anne Arundel Research Institute, Annapolis, MD, USA., Pulido JD; Baptist Medical Center, Jacksonville, FL, USA., Catanzaro AT; Adventist HealthCare, Gaithersburg, MD, USA., Malvestutto CD; Department of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH USA., Li Z; Department of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH USA; Pelotonia Institute for Immuno-Oncology, The Ohio State University Wexner Medical Center, Columbus, OH USA., Cohen JB; Adventist HealthCare, Gaithersburg, MD, USA., Whitman ED; Atlantic Health System, Morristown, NJ, USA., Byrne D; Division of Infectious Diseases, Department of Medicine, Cooper Medical School of Rowan University, Cooper University Healthcare, Camden, NJ, USA., Giddings OK; University Hospitals, Cleveland Medical Center, Case Western Reserve University, Cleveland, OH, USA., Lake JE; Department of Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA., Chua JV; Institute of Human Virology, Division of Infectious Diseases, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA., Li E; Edetek, Princeton, NJ, USA., Chen J; Edetek, Princeton, NJ, USA., Zhou X; Edetek, Princeton, NJ, USA., He K; R&G US, North Potomac, MD, USA., Gates D; Merck & Co, Kenilworth, NJ, USA., Kaur A; Merck & Co, Kenilworth, NJ, USA., Chen J; Edetek, Princeton, NJ, USA; ClinSmart, Newtown, PA, USA., Chou HY; OncoImmune, Rockville, MD, USA., Devenport M; OncoImmune, Rockville, MD, USA., Touomou R; OncoImmune, Rockville, MD, USA., Kottilil S; Institute of Human Virology, Division of Infectious Diseases, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA., Liu Y; OncoImmune, Rockville, MD, USA; Division of Immunotherapy, Institute of Human Virology, UM Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA; Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, USA., Zheng P; OncoImmune, Rockville, MD, USA; Division of Immunotherapy, Institute of Human Virology, UM Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA; Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address: pzheng@oncoc4.com.

Publikováno v: The Lancet. Infectious diseases [Lancet Infect Dis] 2022 May; Vol. 22 (5), pp. 611-621. Date of Electronic Publication: 2022 Mar 11.

Importance of the CCR5-CCL5 axis for mucosal Trypanosoma cruzi protection and B cell activation.

Autor: Sullivan NL; Department of Molecular Microbiology and Immunology, Saint Louis University Medical Center, St. Louis, MO 63104, USA., Eickhoff CS, Zhang X, Giddings OK, Lane TE, Hoft DF

Publikováno v: Journal of immunology (Baltimore, Md. : 1950) [J Immunol] 2011 Aug 01; Vol. 187 (3), pp. 1358-68. Date of Electronic Publication: 2011 Jun 29.

Intranasal vaccinations with the trans-sialidase antigen plus CpG Adjuvant induce mucosal immunity protective against conjunctival Trypanosoma cruzi challenges.

Autor: Giddings OK; Department of Molecular Microbiology and Immunology, Saint Louis University Medical Center, St. Louis, Missouri 63104, USA., Eickhoff CS, Sullivan NL, Hoft DF

Publikováno v: Infection and immunity [Infect Immun] 2010 Mar; Vol. 78 (3), pp. 1333-8. Date of Electronic Publication: 2010 Jan 04.

Anatomical route of invasion and protective mucosal immunity in Trypanosoma cruzi conjunctival infection.

Autor: Giddings OK; Department of Molecular Microbiology and Immunology, St. Louis University Health Science Center, 3635 Vista Ave., FDT-8N, St. Louis, MO 63110, USA., Eickhoff CS, Smith TJ, Bryant LA, Hoft DF

Publikováno v: Infection and immunity [Infect Immun] 2006 Oct; Vol. 74 (10), pp. 5549-60.